JP6801203B2 - pH Response Elution Coated Granules and Foods - Google Patents
pH Response Elution Coated Granules and Foods Download PDFInfo
- Publication number
- JP6801203B2 JP6801203B2 JP2016055139A JP2016055139A JP6801203B2 JP 6801203 B2 JP6801203 B2 JP 6801203B2 JP 2016055139 A JP2016055139 A JP 2016055139A JP 2016055139 A JP2016055139 A JP 2016055139A JP 6801203 B2 JP6801203 B2 JP 6801203B2
- Authority
- JP
- Japan
- Prior art keywords
- alginate
- elution
- responsive
- mpa
- viscosity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010828 elution Methods 0.000 title claims description 43
- 239000007931 coated granule Substances 0.000 title claims description 25
- 235000013305 food Nutrition 0.000 title claims description 15
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 65
- 235000010443 alginic acid Nutrition 0.000 claims description 52
- 229920000615 alginic acid Polymers 0.000 claims description 52
- 229940072056 alginate Drugs 0.000 claims description 47
- 239000002245 particle Substances 0.000 claims description 25
- 239000007864 aqueous solution Substances 0.000 claims description 16
- 239000013543 active substance Substances 0.000 claims description 14
- 239000011162 core material Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 239000011247 coating layer Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 description 15
- 230000002378 acidificating effect Effects 0.000 description 11
- 230000000975 bioactive effect Effects 0.000 description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000005096 rolling process Methods 0.000 description 5
- 235000010413 sodium alginate Nutrition 0.000 description 5
- 239000000661 sodium alginate Substances 0.000 description 5
- 229940005550 sodium alginate Drugs 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229920001800 Shellac Polymers 0.000 description 3
- 229920002494 Zein Polymers 0.000 description 3
- 108010055615 Zein Proteins 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000004208 shellac Substances 0.000 description 3
- 229940113147 shellac Drugs 0.000 description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
- 235000013874 shellac Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000005019 zein Substances 0.000 description 2
- 229940093612 zein Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- -1 E and K Natural products 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本発明は、食品に好適に用いることのできる、酸性である胃では不溶性であり、中性となる腸では溶出を起こすpH応答溶出性を有する被覆造粒物に関する。 The present invention relates to a coated granule having a pH-responsive elution property that can be suitably used for foods and is insoluble in an acidic stomach and elutes in a neutral intestine.
酵素や乳酸菌、ローヤルゼリーなどの生理活性物質は酸に弱いため、胃酸から保護され小腸へ到達することが望まれる。トウガラシやニンニク、鉄といった大量に摂取することで胃に負担をかけてしまう生理活性物質においても、腸まで保護された状態で到達することが望まれる。また、打錠後の錠剤のフィルムコーティングの省略、錠剤やカプセル以外の剤型設計が可能になり消費者の負担が低減されるため、とりわけ粒子径の小さい粉末や顆粒への腸溶性付与が望まれる。生理活性物質を胃では保護し、腸まで到達させるための保護剤として、酸性条件下では溶解せず、中性条件下で溶解する成分が用いられる。例えば、メタクリル酸コポリマー、ツェイン、シェラックなどが一般的に使用されている。 Since physiologically active substances such as enzymes, lactic acid bacteria, and royal jelly are sensitive to acids, it is desirable that they be protected from gastric acid and reach the small intestine. It is desirable that even physiologically active substances such as capsicum, garlic, and iron, which impose a burden on the stomach when ingested in large amounts, reach the intestines in a protected state. In addition, since it is possible to omit the film coating of tablets after tableting and to design dosage forms other than tablets and capsules, which reduces the burden on consumers, it is particularly desirable to impart enteric properties to powders and granules with a small particle size. Is done. As a protective agent for protecting a physiologically active substance in the stomach and reaching the intestine, a component that does not dissolve under acidic conditions but dissolves under neutral conditions is used. For example, methacrylic acid copolymers, zeins, shellac and the like are commonly used.
しかしながら、メタクリル酸コポリマーは医薬品用途に限られ、食品には使用することができない。また、ツェインやシェラックは食品にも使用することができるが、水に不溶性であるため有機溶媒を使用することが一般的であり、有機溶媒の残存や環境への配慮、作業場に対する安全対策の点より、有機溶媒の使用は好ましくない。水溶性でありながら、酸性条件下で不溶化し保護材となりうる物質として、アルギン酸塩やペクチン、ジェランガムなどが考えられる。従来より、上記のような物質を使用した腸溶性付与の提案がなされてきた。 However, methacrylic acid copolymers are limited to pharmaceutical applications and cannot be used in foods. In addition, although zein and shellac can be used for food, it is common to use an organic solvent because it is insoluble in water. In terms of residual organic solvent, consideration for the environment, and safety measures for the workplace. Therefore, the use of an organic solvent is not preferable. Alginate, pectin, gellan gum, and the like can be considered as substances that are water-soluble but insoluble under acidic conditions and can serve as protective materials. Conventionally, proposals for imparting enteric solubility using the above-mentioned substances have been made.
例えば、乳酸菌粉末にアルギン酸ナトリウムを被覆し、さらに徐放性被膜を被覆する方法(特許文献1)、ラクトフェリンを融解させた硬化油により被膜させた方法(特許文献2)、などが提案されている。しかしながら、特許文献1の方法では1次コートとなるアルギン酸ナトリウムは1重量%以下であり、腸溶性の効果はアルギン酸ナトリウムによるものではなくツェインやシェラックなどの徐放性被膜による効果が大きい。また、人口腸液での崩壊時間も遅く、耐酸性の効果も不十分である。特許文献2の方法では、硬化油を溶解させるために品温を70℃まで上げる必要があり、乳酸菌や酵素など熱に弱い物質は製造工程中に活性を失ってしまい、汎用性のある方法ではない。 For example, a method of coating lactic acid bacteria powder with sodium alginate and further coating a sustained-release film (Patent Document 1), a method of coating with hydrogenated oil in which lactoferrin is melted (Patent Document 2), and the like have been proposed. .. However, in the method of Patent Document 1, the amount of sodium alginate used as the primary coat is 1% by weight or less, and the enteric effect is not due to sodium alginate but due to a sustained-release coating such as zein or shellac. In addition, the disintegration time in artificial intestinal juice is slow, and the acid resistance effect is insufficient. In the method of Patent Document 2, it is necessary to raise the product temperature to 70 ° C. in order to dissolve the hydrogenated oil, and heat-sensitive substances such as lactic acid bacteria and enzymes lose their activity during the manufacturing process, and a versatile method is used. Absent.
以上の通り、食品に使用可能な材料を使用しながら、被覆される生理活性物質を損なうことなく、胃では保護し腸まで到達させる被覆粒子が求められている。 As described above, there is a demand for coated particles that protect the stomach and reach the intestines without damaging the bioactive substances to be coated while using materials that can be used for food.
本発明の課題は、アルギン酸塩を使用することで食品素材のみを用いながら、平均粒子径が10〜3000μmの生理活性物質にpH応答溶出性をもたせた被覆造粒物を提供することにある。 An object of the present invention is to provide a coated granulated product in which a physiologically active substance having an average particle size of 10 to 3000 μm is provided with pH-responsive elution property by using alginate and using only a food material.
本発明者らは、上記の課題を解決するために鋭意研究を重ねた結果、特定の粘度のアルギン酸塩を組合せて用いることによって意外にも、上記の課題を解決することの知見を見出し、本発明を完成するに至った。
すなわち、本発明は下記の〔1〕〜〔3〕である。
〔1〕生理活性物質を含有する芯材(S)の外周上に、下記のアルギン酸塩(A1)、(A2)からなるアルギン酸塩(A)の被覆層を有するpH応答溶出性被覆造粒物であって、芯材(S)/アルギン酸塩(A)の質量比が50/50〜97/3であり、平均粒子径が10〜3000μmであるpH応答溶出性被覆造粒物。
アルギン酸塩(A1):20℃における1質量%水溶液の粘度が20〜1000mPa・sとなるアルギン酸塩
アルギン酸塩(A2):20℃における1質量%水溶液の粘度が20mPa・s未満となるアルギン酸塩
〔2〕アルギン酸塩(A)のA1/A2の質量比が10/90〜90/10である、前記の〔1〕に記載のpH応答溶出性被覆造粒物。
〔3〕前記の〔1〕または〔2〕に記載のpH応答溶出性被覆造粒物を用いた食品。
As a result of intensive research to solve the above problems, the present inventors have unexpectedly found that the above problems can be solved by using alginate having a specific viscosity in combination. The invention was completed.
That is, the present invention is the following [1] to [3].
[1] A pH-responsive elution coated granulated product having a coating layer of alginate (A) composed of the following alginates (A1) and (A2) on the outer periphery of a core material (S) containing a physiologically active substance. A pH-responsive elution-coated granule having a mass ratio of core material (S) / alginate (A) of 50/50 to 97/3 and an average particle size of 10 to 3000 μm.
Alginate (A1): Alginate having a viscosity of 1% by mass aqueous solution at 20 ° C. of 20 to 1000 mPa · s Alginate (A2): Alginate having a viscosity of 1% by mass aqueous solution at 20 ° C. of less than 20 mPa · s [ 2] The pH-responsive elution coated granule according to the above [1], wherein the mass ratio of A1 / A2 of alginate (A) is 10/90 to 90/10.
[3] A food product using the pH-responsive elution-coated granules according to the above [1] or [2].
本発明によって、食品に使用可能な材料を使用しながら、被覆される生理活性物質を損なうことなく、胃では保護し腸まで到達させる被覆造粒物が提供される。また、さらに本発明の被覆造粒物をハードカプセルや錠剤、顆粒品などの食品の粉末原料として使用して食品となすことで、食品製品中の生理活性物質について、体内に有効に吸収される処方量を的確に設定でき、消費者にとって魅力のある食品製品を提供できるようになる。 INDUSTRIAL APPLICABILITY The present invention provides a coated granule that protects the stomach and reaches the intestine without damaging the bioactive substance to be coated while using a material that can be used for food. Further, by using the coated granule of the present invention as a powder raw material for foods such as hard capsules, tablets, and granules to make foods, a formulation that effectively absorbs physiologically active substances in food products into the body. It will be possible to set the amount accurately and provide food products that are attractive to consumers.
以下、本発明を詳細に説明する。
本発明のpH応答溶出性被覆造粒物は、生理活性物質を含有する芯材(S)の外周上に、下記のアルギン酸塩(A1)、(A2)からなるアルギン酸塩(A)の被覆層を有するpH応答溶出性被覆造粒物である。
アルギン酸塩(A1):20℃における1質量%水溶液の粘度が20〜1000mPa・sとなるアルギン酸塩
アルギン酸塩(A2):20℃における1質量%水溶液の粘度が20mPa・s未満となるアルギン酸塩
Hereinafter, the present invention will be described in detail.
In the pH-responsive elution coated granule of the present invention, the coating layer of alginate (A) composed of the following alginates (A1) and (A2) is placed on the outer periphery of the core material (S) containing a physiologically active substance. It is a pH-responsive elution coated granulated product having.
Alginate (A1): Alginate having a viscosity of 1% by mass aqueous solution at 20 ° C. of 20 to 1000 mPa · s Alginate (A2): Alginate having a viscosity of 1% by mass aqueous solution at 20 ° C. of less than 20 mPa · s
<生理活性物質を含有する芯材(S)>
本発明のpH応答溶出性被覆造粒物において、芯材(S)は、粉末状の生理活性物質または、生理活性物質を不活性な固体材料と混合して濃度調整した生理活性物質である。芯材(S)に含まれる生理活性物質としては、酵素や機能性ペプチド、乳酸菌、ローヤルゼリーといった酸に弱い生理活性物質、トウガラシやニンニク、鉄といった大量に摂取した場合に胃に負担を与える生理活性物質が挙げられる。その他にも腸で吸収される生理活性物質が挙げられ、例えば、チアミン、リボフラビン、ピリドキシン、シアノコバラミン、ナイアシン、葉酸、パントテン酸、ビオチン、アスコルビン酸といった水溶性ビタミンおよびこれらの誘導体、ビタミンA、D、E、Kなどの脂溶性ビタミン、アミノ酸、コラーゲン、ヒアルロン酸、ハーブ類、天然抽出エキス末などがある。
<Core material (S) containing a physiologically active substance>
In the pH-responsive elution-coated granules of the present invention, the core material (S) is a powdered bioactive substance or a bioactive substance whose concentration is adjusted by mixing the bioactive substance with an inert solid material. The bioactive substances contained in the core material (S) include enzymes, functional peptides, lactic acid bacteria, royal jelly and other bioactive substances that are sensitive to acids, and capsicum, garlic, iron and other bioactive substances that impose a burden on the stomach when ingested in large amounts. Substances are mentioned. Other physiologically active substances that are absorbed in the intestine include water-soluble vitamins such as thiamine, riboflavin, pyridoxine, cyanocobalamin, niacin, folic acid, pantothenic acid, biotin, and ascorbic acid and their derivatives, vitamins A and D, There are fat-soluble vitamins such as E and K, amino acids, collagen, hyaluronic acid, herbs, and natural extract powder.
本発明のpH応答溶出性被覆造粒物にもちいる芯材(S)として、生理活性物質に混合して濃度調整して用いる不活性な固体材料としては、一般的な賦形剤であるセルロース、デキストリン等が挙げられる。本発明のpH応答溶出性被覆造粒物において、芯材(S)中の生理活性物質の濃度は、配合する生理活性物質の目安摂取量に応じて適宜合わせてよい。 Cellulose, which is a general excipient, is used as a core material (S) used in the pH-responsive elution coated granules of the present invention as an inert solid material mixed with a physiologically active substance and adjusted in concentration. , Dextrin and the like. In the pH-responsive elution coated granule of the present invention, the concentration of the bioactive substance in the core material (S) may be appropriately adjusted according to the standard intake amount of the bioactive substance to be blended.
<アルギン酸塩(A)>
アルギン酸塩としては、アルギン酸ナトリウム、アルギン酸カリウム、アルギン酸アンモニウム等の一価かつ水溶性塩が好ましい。本発明におけるアルギン酸水溶液の粘度は、BL型回転粘度計(東機産業(株)製「BLII」、回転数:60rpm、60秒、粘度が200mPa・s未満の場合はローターNo.1、200mPa・s以上の場合はローターNo.2)を用いて測定することができる。
アルギン酸塩の粘度は、アルギン酸塩の分子量により変化し、分子量が大きいものは高い粘度を示し、分子量が低いものは低い粘度を示す。上記アルギン酸塩(A1)の重量平均分子量(Mw)は50以上となり、アルギン酸塩(A2)の重量平均分子量は50以下となる。
<Alginate (A)>
As the alginate, monovalent and water-soluble salts such as sodium alginate, potassium alginate, and ammonium alginate are preferable. The viscosity of the alginic acid aqueous solution in the present invention is a BL type rotational viscometer (“BLII” manufactured by Toki Sangyo Co., Ltd., rotation speed: 60 rpm, 60 seconds, rotor No. 1, 200 mPa · s when the viscosity is less than 200 mPa · s. In the case of s or more, it can be measured using the rotor No. 2).
The viscosity of alginate varies depending on the molecular weight of alginate, and those having a large molecular weight show a high viscosity and those having a low molecular weight show a low viscosity. The weight average molecular weight (Mw) of the alginate (A1) is 50 or more, and the weight average molecular weight of the alginate (A2) is 50 or less.
<アルギン酸塩(A1)>
本発明に用いるアルギン酸塩(A1)は、20℃における1質量%水溶液の粘度は20mPa・s〜1000mPa・sであり、20mPa・s〜400mPa・sが好ましく、50mPa・s〜200mPa・sがさらに好ましい。
<Alginate (A1)>
The alginate (A1) used in the present invention has a viscosity of 1% by mass aqueous solution at 20 ° C. of 20 mPa · s to 1000 mPa · s, preferably 20 mPa · s to 400 mPa · s, and more preferably 50 mPa · s to 200 mPa · s. preferable.
<アルギン酸塩(A2)>
本発明に用いるアルギン酸塩(A2)は、20℃における1質量%水溶液の粘度が20mPa・s未満であり、1mPa・s〜10mPa・sが好ましい。
<Alginate (A2)>
The alginate (A2) used in the present invention has a viscosity of a 1% by mass aqueous solution at 20 ° C. of less than 20 mPa · s, and is preferably 1 mPa · s to 10 mPa · s.
20℃における1質量%水溶液の粘度が20〜1000mPa・sとなるアルギン酸塩(A1)を用いることで耐酸性を十分にすることができ、20℃における1質量%水溶液の粘度が20mPa・s未満となるアルギン酸塩(A2)を用いることで被膜の柔軟性が高まることで被膜性が向上し、酸性条件での生理活性物質の溶出をより抑制することができ、かつ、中性条件での溶出を早めることができる。また粒子径のコントロールも容易になる。
アルギン酸塩(A1)およびアルギン酸塩(A2)の質量比A1/A2は、特に制限されないが、10/90〜90/10が好ましく、10/90〜50/50がより好ましく、10/90〜30/70が特に好ましい。質量比A1/A2が10/90を下回ると耐酸性が低下し、酸性条件の溶出が起こりやすくなる。一方、90/10を上回ると、被膜の柔軟性が乏しく結着性が高まるため、粒子に均一に被覆することができずに粒子の粗大化が起こりやすく、また中性条件での溶出遅延が生じる。
Alginate (A1) having a viscosity of 1% by mass aqueous solution at 20 ° C. of 20 to 1000 mPa · s can be sufficiently acid resistant, and the viscosity of the 1% by mass aqueous solution at 20 ° C. is less than 20 mPa · s. By using alginate (A2), the flexibility of the film is increased, the film property is improved, the elution of physiologically active substances under acidic conditions can be further suppressed, and the elution under neutral conditions can be further suppressed. Can be accelerated. In addition, the particle size can be easily controlled.
The mass ratio A1 / A2 of alginate (A1) and alginate (A2) is not particularly limited, but is preferably 10/90 to 90/10, more preferably 10/90 to 50/50, and 10/90 to 30. / 70 is particularly preferable. When the mass ratio A1 / A2 is less than 10/90, the acid resistance is lowered, and elution of acidic conditions is likely to occur. On the other hand, if it exceeds 90/10, the flexibility of the coating film is poor and the binding property is enhanced, so that the particles cannot be uniformly coated and the particles are likely to be coarsened, and the elution delay under neutral conditions is delayed. Occurs.
本発明のpH応答溶出性被覆造粒物においては、生理活性物質からなる芯材(S)およびアルギン酸塩(A)の質量比率S/Aは、50/50〜97/3であり、好ましくは60/40〜95/5であり、より好ましくは70/30〜90/10である。アルギン酸塩(A)が3%未満では耐酸性が十分に得られない。アルギン酸塩(A)が50%を超える場合では中性条件での溶出が遅延されたり、製造工程が長時間化し、粒子径のコントロールが難しくなり粒子の粗大化が発生したりする。 In the pH-responsive elution-coated granules of the present invention, the mass ratio S / A of the core material (S) and alginate (A) made of a physiologically active substance is 50/50 to 97/3, preferably 50/50 to 97/3. It is 60/40 to 95/5, more preferably 70/30 to 90/10. If the alginate (A) is less than 3%, sufficient acid resistance cannot be obtained. If the alginate (A) exceeds 50%, elution under neutral conditions may be delayed, the manufacturing process may take a long time, the particle size may be difficult to control, and the particles may become coarse.
<pH応答溶出性被覆造粒物>
また、本発明のpH応答溶出性被覆造粒物は、平均粒子径が10〜3000μmであり、好ましくは50〜1500μm、より好ましくは100〜800μmである。平均粒子径が小さすぎると粒子の表面積が大きくなり、酸性条件で十分に溶出を抑制させることが難しく、大きすぎると工程中の荷重により粒子に欠損が生じ、良好な被膜形成ができない。
本発明における平均粒子径とは、体積平均径を意味し、レーザー回折式粒度分布測定装置を用いて測定することができる。
<pH-responsive elution coated granules>
The pH-responsive elution coated granule of the present invention has an average particle diameter of 10 to 3000 μm, preferably 50 to 1500 μm, and more preferably 100 to 800 μm. If the average particle size is too small, the surface area of the particles becomes large, and it is difficult to sufficiently suppress elution under acidic conditions. If the average particle size is too large, the particles are chipped due to the load during the process, and good film formation cannot be performed.
The average particle size in the present invention means a volume average diameter, and can be measured by using a laser diffraction type particle size distribution measuring device.
本発明のpH応答溶出性被覆造粒物の製法は、公知の流動造粒コーティング方法を用いることができる。例えば、流動運動又は転動運動する芯材(S)に、アルギン酸塩(A)の溶解した溶液を吹き付け、芯材(S)の外周上で該溶液を乾燥することによりアルギン酸塩(A)の被覆層を形成する。具体的には、流動層造粒コーティング装置(例えばフロイント産業(株)「FLOW COATER」など)、転動流動層造粒機、遠心転動造粒コーティング装置、などを用いた公知の方法により行うことができる。装置下部に回転盤が設置された装置が好ましく、回転盤の遠心力が加わることで粒子の結合よる造粒が抑制されるため、粒子径のコントロールが容易になる。また、粒子の転動により被膜が展延作用を受けるため、芯材粒子の表面に均一に被膜を形成させることができる。 As a method for producing a pH-responsive elution coated granule of the present invention, a known flow granulation coating method can be used. For example, a solution of alginate (A) is sprayed onto a core material (S) that is in a fluid or rolling motion, and the solution is dried on the outer circumference of the core material (S) to obtain alginate (A). Form a coating layer. Specifically, it is carried out by a known method using a fluidized bed granulation coating device (for example, Freund Sangyo Co., Ltd. "FLOW COATER"), a rolling fluidized bed granulator, a centrifugal rolling granulation coating device, or the like. be able to. A device in which a rotating disk is installed at the bottom of the device is preferable, and the centrifugal force of the rotating disk suppresses granulation due to the binding of particles, so that the particle size can be easily controlled. Further, since the film is spread by the rolling of the particles, the film can be uniformly formed on the surface of the core material particles.
本発明のpH応答溶出性被覆造粒物は、胃のような酸性条件下では溶出せずに保護され、腸のような中性条件下では速やかに溶出するpH応答溶出性を必要とする食品において、pH応答溶出性被覆造粒物をそのまま、あるいは各種製剤に加工して利用することができる。 The pH-responsive elution coated granules of the present invention are protected without elution under acidic conditions such as stomach, and are rapidly eluted under neutral conditions such as intestines. Foods requiring pH-responsive elution. In, the pH-responsive elution coated granules can be used as they are or after being processed into various preparations.
以下に実施例を挙げて本発明を具体的に説明する。
以下に示す各例において、用いた試験方法、評価方法を次に示す。
The present invention will be specifically described below with reference to examples.
The test method and evaluation method used in each of the examples shown below are shown below.
(1)溶出試験
実施例および比較例で得られたpH応答溶出性被覆造粒物に含まれる生理活性物質の溶出試験液への溶出性について、「日本薬局方 6.10 溶出試験法」により定められた方法に準じて行った。試験液としては胃液相当のpH1.2水溶液または腸液相当のpH6.8水溶液を900mL用いた。本発明における腸溶性とは、pH1.2水溶液にて1時間後の溶出率が50%以下、pH6.8水溶液にて30分後の溶出率が70%以上をいう。
(2)平均粒子径
(株)島津製作所のレーザー回折式粒度分布測定器「SALD−2100」にて測定した。
(1) Dissolution test The elution of the physiologically active substance contained in the pH-responsive elution coated granules obtained in Examples and Comparative Examples into the elution test solution was determined by the "Japanese Pharmacopoeia 6.10 Elution Test Method". It was performed according to the prescribed method. As the test solution, 900 mL of a pH 1.2 aqueous solution equivalent to gastric juice or a pH 6.8 aqueous solution equivalent to intestinal juice was used. The enteric property in the present invention means that the elution rate after 1 hour in a pH 1.2 aqueous solution is 50% or less, and the elution rate after 30 minutes in a pH 6.8 aqueous solution is 70% or more.
(2) Average particle size The measurement was performed with a laser diffraction type particle size distribution measuring device "SALD-2100" manufactured by Shimadzu Corporation.
実施例および比較例において、pH応答溶出性被覆造粒物の調製に用いた材料の詳細を次に示す。表中には略号で示した。
リボフラビン: BASF製「リボフラビンHF100」
大豆ペプチド: 不二製油(株)製「ハイニュートDL」
クエン酸第一鉄ナトリウム: エーザイフードケミカル(株)製「サンフェロール」
プラセンタエキス末: スノーデン製「スノープラセンタゴールド純末PJ」
セルロース: 旭化成ケミカルズ製「セオラスST−02」
CA−IL−6: (株)キミカ製商品名「キミカアルギンIL−6」(粘度65mPa・s、重量平均分子量約69万)
TA−NSPHR: キッコーマンバイオケミファ(株)製商品名「タックアルギン−NSPHR」(粘度550mPa・s、重量平均分子量約188万)
CA−IL−2: (株)キミカ製商品名「キミカアルギンIL−2」(粘度30mPa・s、重量平均分子量約55万)
CA−I−8: (株)キミカ製商品名「キミカアルギンI−8」(粘度850mPa・s、重量平均分子量約210万)
CA−I−1: (株)キミカ製商品名「キミカアルギンI−1」(粘度120mPa・s、重量平均分子量約107万)
CA−ULV−1: (株)キミカ製商品名「キミカアルギンULV−1」(粘度10mPa・s、重量平均分子量約18万)
CA−ULV−L3: (株)キミカ製商品名「キミカアルギンULV−L3」(粘度1mPa・s、重量平均分子量約4万)
Details of the materials used to prepare the pH-responsive elution coated granules in Examples and Comparative Examples are shown below. It is indicated by an abbreviation in the table.
Riboflavin: BASF's "Riboflavin HF100"
Soy Peptide: "High Newt DL" manufactured by Fuji Oil Co., Ltd.
Sodium ferrous citrate: "Sanferol" manufactured by Eisai Food & Chemical Co., Ltd.
Placenta extract powder: Snowden's "Snow Placenta Gold Pure Powder PJ"
Cellulose: "Theoras ST-02" manufactured by Asahi Kasei Chemicals
CA-IL-6: Product name "Kimika Argin IL-6" manufactured by Kimika Co., Ltd. (viscosity 65 mPa · s, weight average molecular weight about 690,000)
TA-NSPHR: Product name "Tuck Argin-NSPHR" manufactured by Kikkoman Biochemifa Co., Ltd. (viscosity 550 mPa · s, weight average molecular weight about 1.88 million)
CA-IL-2: Product name "Kimika Argin IL-2" manufactured by Kimika Co., Ltd. (viscosity 30 mPa · s, weight average molecular weight about 550,000)
CA-I-8: Product name "Kimika Argin I-8" manufactured by Kimika Co., Ltd. (viscosity 850 mPa · s, weight average molecular weight about 2.1 million)
CA-I-1: Product name "Kimika Argin I-1" manufactured by Kimika Co., Ltd. (viscosity 120 mPa · s, weight average molecular weight about 1.07 million)
CA-ULV-1: Product name "Kimika Argin ULV-1" manufactured by Kimika Co., Ltd. (viscosity 10 mPa · s, weight average molecular weight about 180,000)
CA-ULV-L3: Product name "Kimika Argin ULV-L3" manufactured by Kimika Co., Ltd. (viscosity 1 mPa · s, weight average molecular weight about 40,000)
[実施例1]
リボフラビン291gをセルロース291gと混合し転動流動層造粒機に仕込み、被覆液360gを噴霧し、被覆した。噴霧液の組成はアルギン酸ナトリウム(キミカアルギンIL−6[粘度65mPa・s]9%、キミカアルギンULV−1[粘度10mPa・s]1%)5%、水95%、である。配合組成を評価結果とともに表1に示す。
上記記載の粘度は、20℃における1質量%水溶液の粘度であり、BL型回転粘度計(東機産業(株)製「BLII」、回転数:60rpm、60秒、粘度が200mPa・s未満の場合はローターNo.1、200mPa・s以上の場合はローターNo.2)を用いて測定した粘度である。
[Example 1]
291 g of riboflavin was mixed with 291 g of cellulose and charged into a rolling fluidized bed granulator, and 360 g of a coating liquid was sprayed and coated. The composition of the spray solution is sodium alginate (Kimika algin IL-6 [viscosity 65 mPa · s] 9%, Kimika algin ULV-1 [viscosity 10 mPa · s] 1%) 5%, water 95%. The compounding composition is shown in Table 1 together with the evaluation results.
The viscosity described above is the viscosity of a 1% by mass aqueous solution at 20 ° C., and is a BL type rotational viscometer (“BLII” manufactured by Toki Sangyo Co., Ltd., rotation speed: 60 rpm, 60 seconds, viscosity less than 200 mPa · s. In this case, the viscosity is measured using rotor No. 1, and in the case of 200 mPa · s or more, the viscosity is measured using rotor No. 2).
[実施例2〜8]
実施例1と同じ操作にて、材料の種類または量を変えて本発明のpH応答溶出性被覆造粒物を調製した。配合組成を評価結果とともに表1に示す。
[Examples 2 to 8]
The pH-responsive elution coated granules of the present invention were prepared by changing the type or amount of the material in the same operation as in Example 1. The compounding composition is shown in Table 1 together with the evaluation results.
[比較例1〜4]
実施例1と同じ操作にて、材料の種類または量を変えて本発明のものでないpH応答溶出性被覆造粒物を調製した。配合組成を評価結果とともに表2に示す。
[Comparative Examples 1 to 4]
In the same operation as in Example 1, the type or amount of the material was changed to prepare a pH-responsive elution coated granule not of the present invention. The compounding composition is shown in Table 2 together with the evaluation results.
実施例1〜8に示した結果より、本発明のpH応答溶出性被覆造粒物は酸性条件下では溶出せず、中性条件下では速やかに溶出することがわかった。 From the results shown in Examples 1 to 8, it was found that the pH-responsive elution coated granules of the present invention did not elute under acidic conditions, but elute rapidly under neutral conditions.
一方、アルギン酸塩(A2)を配合していない比較例1では粒子径のコントロールが難しく粗大化が起こった。また、アルギン酸塩の柔軟性が不十分なため被膜性が悪く酸性条件での溶出抑制が不十分であった。比較例2ではアルギン酸塩(A1)を配合していないため、耐酸性が不十分であり酸性条件で溶出がみられた。比較例3ではアルギン酸塩の含量が少ないため、溶出制御能が不十分であり酸性条件下での溶出制御が不十分であった。比較例4ではアルギン酸塩の含量が多すぎるため、粒子径の粗大化および中性条件での溶出遅延がみられた。 On the other hand, in Comparative Example 1 in which alginate (A2) was not blended, it was difficult to control the particle size and coarsening occurred. In addition, since the flexibility of alginate was insufficient, the film property was poor and the elution suppression under acidic conditions was insufficient. In Comparative Example 2, since alginate (A1) was not blended, acid resistance was insufficient and elution was observed under acidic conditions. In Comparative Example 3, since the content of alginate was small, the elution control ability was insufficient and the elution control under acidic conditions was insufficient. In Comparative Example 4, the content of alginate was too high, so that the particle size was coarsened and the elution was delayed under neutral conditions.
Claims (2)
アルギン酸塩(A1):20℃における1質量%水溶液の粘度が20〜1000mPa・sとなるアルギン酸塩
アルギン酸塩(A2):20℃における1質量%水溶液の粘度が20mPa・s未満となるアルギン酸塩 A pH-responsive elution coated granule having a coating layer of alginate (A) composed of the following alginate (A1) and (A2) on the outer periphery of the core material (S) containing a physiologically active substance. , The mass ratio of core material (S) / alginate (A) is 50/50 to 90/10 , and the mass ratio of A1 / A2 of alginate (A) is 10/90 to 30/70, which is an average. pH responsive eluting coating granules having a particle diameter of a 10~ 8 00μm.
Alginate (A1): Alginate having a viscosity of 1% by mass aqueous solution at 20 ° C. of 20 to 1000 mPa · s Alginate (A2): Alginate having a viscosity of 1% by mass aqueous solution at 20 ° C. of less than 20 mPa · s
A food containing the pH-responsive elution-coated granules according to claim 1 in the state of the pH-responsive-eluting coated granules .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016055139A JP6801203B2 (en) | 2016-03-18 | 2016-03-18 | pH Response Elution Coated Granules and Foods |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016055139A JP6801203B2 (en) | 2016-03-18 | 2016-03-18 | pH Response Elution Coated Granules and Foods |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017165701A JP2017165701A (en) | 2017-09-21 |
JP6801203B2 true JP6801203B2 (en) | 2020-12-16 |
Family
ID=59909660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016055139A Active JP6801203B2 (en) | 2016-03-18 | 2016-03-18 | pH Response Elution Coated Granules and Foods |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6801203B2 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5176415A (en) * | 1974-12-26 | 1976-07-02 | Riken Vitamin Oil Co Ltd | Choyoseiseizaino seizohoho |
JP2002193831A (en) * | 2000-12-27 | 2002-07-10 | Fancl Corp | Hemoferrum-containing composition for oral |
JP2002205948A (en) * | 2001-01-05 | 2002-07-23 | Kibun Food Chemifa Co Ltd | Sustained release composition and method for producing the same |
CA2705518A1 (en) * | 2007-11-13 | 2009-05-22 | Hercules Incorporated | Water dispersible enteric coating formulation for nutraceutical and pharmaceutical dosage forms |
US20130115285A1 (en) * | 2010-02-12 | 2013-05-09 | Eric H. Van Ness | Enteric coating compositions and methods of making and using the same |
KR101873075B1 (en) * | 2010-08-18 | 2018-06-29 | 에보니크 룀 게엠베하 | Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid |
JP6304234B2 (en) * | 2013-03-08 | 2018-04-04 | ライオン株式会社 | Coating composition, coating preparation and method for producing the same |
CA2932681C (en) * | 2013-12-06 | 2022-08-30 | Moti Harel | Composition for oral delivery of bioactive agents |
EP3357515A4 (en) * | 2015-09-30 | 2019-06-19 | Daicel Corporation | Particle composition for easy-to-use solid preparation and easy-to-use solid preparation including said particle composition |
-
2016
- 2016-03-18 JP JP2016055139A patent/JP6801203B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017165701A (en) | 2017-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
El-Gibaly | Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery | |
TWI394595B (en) | Enteric granules and methods for their manufacture | |
JPH11315032A (en) | Production of enteric coated pancreatin granule | |
JP6304234B2 (en) | Coating composition, coating preparation and method for producing the same | |
WO2019013260A1 (en) | Enteric hard capsule | |
EP3236954B1 (en) | Enteric film coating compositions, method of coating, and coated forms | |
TW201625308A (en) | Coated preparation and method for producing same | |
WO1999017752A1 (en) | Improved dosage units | |
JP2023016043A (en) | Gamma-polyglutamic acid and zinc compositions | |
JP6801203B2 (en) | pH Response Elution Coated Granules and Foods | |
JP2019523275A (en) | Sustained release composition of active ingredient | |
CA3013795A1 (en) | Time release vitamins and minerals in edible oils | |
TW201408284A (en) | Solid pharmaceutical preparation | |
JP2002003366A (en) | Aqueous coating composition for solid medicine | |
Rajabi-Siahboomi et al. | Ethylcellulose applications in multiparticulate systems | |
JP5873868B2 (en) | A composition comprising shellac and / or a salt thereof and sodium starch glycolate | |
JP5991573B2 (en) | Coated particles | |
CN106999442A (en) | Method for preparing pharmaceutical polymer composition | |
TWI402084B (en) | Microcapsules and method of preparing the same | |
JP2020050657A (en) | Enteric-coated powder | |
US11833252B2 (en) | Aqueous enteric coating composition | |
KR102555664B1 (en) | granule formulation | |
JP4822095B2 (en) | Antipyretic analgesic solid preparation | |
JP7110366B2 (en) | Alcohol-tolerant oral pharmaceutical composition of lorazepam | |
JP2020203852A (en) | pH-RESPONSIVE ELUENTS, pH-RESPONSIVE ELUENT-COATED GRANULES, FOODS, AND PHARMACEUTICALS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200317 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20200330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200515 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201027 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201109 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6801203 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |